Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study

Fig. 2

Patient disposition. FAS, full analysis set. *39 patients did not meet eligibility criteria; 29 patients had not initiated treatment with first-line systemic cytotoxic chemotherapy for metastatic breast cancer in the past 90 days and, at that time, were considered to have exhausted endocrine therapy options if hormone receptor-positive; 9 patients had no evidence of metastatic disease; and 1 patient consented after the termination of the study

Back to article page